Conference abstract · 11 Jul 2016
Conference abstractPublished 7 Dec 2018
Bispecific anti-17 A/F nanoantibody - The first nanoantibody in treatment of psoriasis.
Comenius University in Bratislava, Slovak Republic
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nanoantibodies are a new class of antibody -derived biologics. Nanotechnology was originally developed following the discovery and identification that Camelidae possess fully functional antibody that consists of heavy chain only and lack light chain. They form the basis of a new generation of therapeutic molecules â??nanoantibodiesâ?�. The anti-IL-17 A/F nanoantibody neutralizes the pro-inflammatory cytokines IL-17A and IL-17 F, which have been implicated in the pathogenesis of psoriasis. This multicentric, phase I and II, randomized, double -blind, placebo-controlled study investigated multiple ascending doses of anti-IL-17 A/F nanoantibody in patients with moderate-to-severe psoriasis vulgaris. The 33 patients were evaluated; mean age 44,8 year, male/female ratio 29/4. Body surface area (BSA) â?¥10%, Psoriasis Area and Severity Index (PASI)â?¥12, and static Physician´s Global Assessment (sPGA) â?¥3 were evaluated. Patients received 30, 60, 120 or 240 mg anti-IL-17 A/F nanoantibody or placebo every two weeks subcutaneously for 6 weeks. Primary endpoints were safety, tolerability, immunogenicity, and pharmacokinetics (demonstrated on 2017 Annual Meeting of American Academy of Dermatology). Secondary endpoints were pharmacodynamics, efficacy and histologic analysis. On day 85, 6 weeks after the last dose of the drug, PASI 75 was achieved in 7/8 patients (88%) receiving 30 or 60 mg, 8/8 (100%) receiving 120 mg, and 9/9 (100%) receiving 240 mg of drug. PASI 90 was achieved in 4/8 (50%), 7/8 (88%) and 9/9 (100%) patients receiving 30 mg, 60 mg, 120 mg or 240 mg, respectively. PASI 100 was achieved in 1/8 (13%), 2/8 (25%), 4/8 (50%) and 5/9 (56%) patients receiving 30 mg, 60 mg, 120 mg or 240 mg, respectively. No placebo-treated patient achieved PASI 75, 90 or 100 on Day 85. Improved PASI scores were seen 7 days post-first dose in all 4 cohorts. Biopsy assessment of skin lesion showed complete reversal of disease pathology in majority of patients in high dose groups. Conclusion: Anti-IL-17 A/F bispecific nanoantibody is well tolerated and effective in patients with moderate-to severe psoriasis and was associated with clear skin improvement in all indices of psoriasis studied. The trial was supported by Merck/EMD Serano.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 26 Nov 2020
11th Asian Breast Cancer: Screening, Treatment and Management Summit, November 16-17, 2020 Webinar
Research article · 13 Jul 2022
Effects of the Treatment of Dong Medicine Five-Flavour Anti-Diarrhoea Soup Combined with Melalazine on Serum Complement C3, C4, Interleukin-23 and Interleukin-17 in Patients with Ulcerative Colitis
Mini review · 5 Mar 2018
Autoimmune Mechanisms of Psoriasis: Pathogenic Role of the IL-23/IL-17 Axis
Conference abstract · 1 Mar 2018
Apremilast induces IL-10+ Bregs that are inversely correlated with IFN-γ+ and IL-17+ NKT cells in psoriatic arthritis and psoriasis
More from this journal
The newest in Journal of Oncology Translational Research.
Research article · 15 May 2026
Pan-cancer analysis of molecular characteristics and oncogenic role of PRMT5 in human cancers
Research article · 15 Dec 2025
Cardiac Substructure Analysis of Radiation-associated Cardiac Disease in Thoracic Malignancy Patients
Brief report · 29 Nov 2025
CDx: Navigating Global Regulations for Precision Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Oncology Translational Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Danka Svecova”

